Brown Advisory Inc. Buys 347,779 Shares of Danaher Corporation $DHR

Brown Advisory Inc. boosted its stake in shares of Danaher Corporation (NYSE:DHR) by 11.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,487,241 shares of the conglomerate’s stock after purchasing an additional 347,779 shares during the quarter. Danaher comprises 1.1% of Brown Advisory Inc.’s portfolio, making the stock its 17th largest holding. Brown Advisory Inc.’s holdings in Danaher were worth $798,304,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank Pictet & Cie Europe AG raised its position in shares of Danaher by 25.4% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 366,481 shares of the conglomerate’s stock valued at $83,895,000 after buying an additional 74,301 shares during the last quarter. Maxi Investments CY Ltd acquired a new stake in Danaher during the third quarter worth about $3,251,000. Defender Capital LLC. acquired a new stake in Danaher during the fourth quarter worth about $35,715,000. CIBC Bancorp USA Inc. bought a new position in Danaher during the third quarter valued at about $17,480,000. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in Danaher by 303.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock valued at $56,777,000 after acquiring an additional 186,584 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on DHR shares. UBS Group reduced their price objective on Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Wells Fargo & Company cut their target price on Danaher from $240.00 to $212.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 22nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a research report on Friday, March 27th. Morgan Stanley decreased their price target on shares of Danaher from $270.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 22nd. Finally, Argus lowered their price target on shares of Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Friday, April 24th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $233.61.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Danaher Trading Down 0.5%

Shares of DHR opened at $179.95 on Friday. The company has a current ratio of 1.87, a quick ratio of 1.52 and a debt-to-equity ratio of 0.33. The stock has a market cap of $127.37 billion, a PE ratio of 34.81, a PEG ratio of 2.40 and a beta of 0.81. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The stock has a 50 day simple moving average of $180.93 and a 200-day simple moving average of $204.78.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, April 20th. The conglomerate reported $2.06 EPS for the quarter, beating the consensus estimate of $1.94 by $0.12. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the previous year, the firm earned $1.88 EPS. Danaher’s quarterly revenue was up 3.7% on a year-over-year basis. On average, sell-side analysts predict that Danaher Corporation will post 8.45 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. Danaher’s dividend payout ratio (DPR) is presently 30.95%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.